From Nasdaq: 2024-05-16 08:02:37

Analysts have provided varied ratings for OncoCyte (NASDAQ:OCX) over the past quarter, ranging from bullish to bearish. Recent ratings show 2 bullish, 1 somewhat bullish, and 1 indifferent rating, with an average 12-month price target of $4.38 and a high estimate of $5.00.

Recent analyst actions highlight changes in sentiment towards OncoCyte. Analysts like Mike Matson from Needham have raised their price targets, reflecting positive outlooks on the company’s future performance. Maintaining, raising, or lowering ratings reveal analysts’ reactions to market conditions and company developments.

OncoCyte Corp focuses on liquid biopsy diagnostics for early cancer detection, utilizing blood or urine samples. Financially, the company has shown revenue growth of 14.6% over a 3-month period, but faces challenges with a negative net margin. ROE surpasses industry standards, while ROA falls below average, indicating room for improvement in asset utilization.

Read more at Nasdaq.: 4 Analysts Assess OncoCyte: What You Need To Know